Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal
Authors
Keywords
Mitoxantrone, Evidence Review Group, Cabazitaxel, Appraisal Committee, Karnofsky Performance Status Score
Journal
PHARMACOECONOMICS
Volume 31, Issue 6, Pages 479-488
Publisher
Springer Nature
Online
2013-04-11
DOI
10.1007/s40273-013-0050-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer
- (2013) Eldon Spackman et al. PHARMACOECONOMICS
- Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal
- (2013) Nigel Armstrong et al. PHARMACOECONOMICS
- Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization
- (2013) Dawn Craig et al. PHARMACOECONOMICS
- Trabectedin for the Treatment of Advanced Metastatic Soft Tissue Sarcoma: A NICE Single Technology Appraisal
- (2013) Rachid Rafia et al. PHARMACOECONOMICS
- Bivalirudin for the Treatment of ST-Segment Elevation Myocardial Infarction: A NICE Single Technology Appraisal
- (2013) E. L. Simpson et al. PHARMACOECONOMICS
- Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma
- (2013) Janette Greenhalgh et al. PHARMACOECONOMICS
- Bevacizumab for Metastatic Colorectal Cancer
- (2012) Sophie Whyte et al. PHARMACOECONOMICS
- Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura
- (2012) Dwayne Boyers et al. PHARMACOECONOMICS
- Golimumab for the Treatment of Psoriatic Arthritis
- (2012) Huiqin Yang et al. PHARMACOECONOMICS
- Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma
- (2012) Mary Kilonzo et al. PHARMACOECONOMICS
- Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years
- (2012) Jane Burch et al. PHARMACOECONOMICS
- TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer
- (2011) Stephane Oudard Future Oncology
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy
- (2011) Rumona Dickson et al. PHARMACOECONOMICS
- Denosumab for the Prevention of Osteoporotic Fractures in Post-Menopausal Women
- (2011) Graham Scotland et al. PHARMACOECONOMICS
- Dronedarone for the Treatment of Atrial Fibrillation
- (2011) Claire McKenna et al. PHARMACOECONOMICS
- Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery
- (2011) Michael Holmes et al. PHARMACOECONOMICS
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
- (2010) Adrian Bagust et al. PHARMACOECONOMICS
- Single Technology Appraisal at the UK National Institute for Health and Clinical Excellence
- (2010) Mark Sculpher PHARMACOECONOMICS
- Alitretinoin for Severe Chronic Hand Eczema
- (2010) Mark Rodgers et al. PHARMACOECONOMICS
- Febuxostat for the Management of Hyperuricaemia in Patients with Gout
- (2010) Matt Stevenson et al. PHARMACOECONOMICS
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started